Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials: a GRAPPA-OMERACT systematic review and network meta-analysis
Annals of the Rheumatic Diseases · 2026-08 · 85 (8) · 1530-1542
DOI: 10.1016/j.ard.2026.05.013 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Annals of the Rheumatic Diseases, 2026-08. Verfasst von Tommy K Annfeldt und 17 weiteren Autor:innen. Beteiligte Einrichtung: Section for Biostatistics and Evidence-Based Research, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark. Electronic a…. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Antirheumatic Agents, Outcome Assessment, Health Care, Biological Products. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Oak Foundation USA.
Abstract (Originalsprache)
OBJECTIVES: To identify which composite outcome measure most effectively distinguishes active treatments from placebo in randomised controlled trials (RCTs) of biologic or targeted synthetic disease-modifying antirheumatic drugs (b- or tsDMARDs) for psoriatic arthritis (PsA). METHODS: A systematic literature review (PROSPERO ID: CRD42024578203) of Cochrane Central Register of Controlled Trials and PubMed identified RCTs comparing b- or tsDMARDs with placebo reporting ≥2 of 7 composite outcome measures shortlisted for evaluation by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis-Outcome Measures in Rheumatology (GRAPPA-OMERACT) working group (American College of Rheumatology Response Criteria [ACR], Composite Psoriatic Disease Activity Index [CPDAI], Disease Activity index for PSoriatic Arthritis [DAPSA], Minimal Disease Activity [MDA], Psoriatic Arthritis Disease Activity Score [PASDAS], and 3- and 4-Visual Analogue Scale [VAS]). Discriminant capacities were assessed using odds ratio (OR) for binary outcomes, with continuous outcomes converted from standardised mean differences and analysed through network and multivariate meta-analysis techniques. RESULTS: Of 2483 references, 24 trials were included (43 randomised comparisons). CPDAI was rarely reported, and no RCTs reported 3-VAS and 4-VAS. The main network meta-analysis showed differences in discriminant properties for DAPSA vs ACR20 (OR: 0.80; 95% CI: 0.66-0.97; favouring ACR20), DAPSA vs MDA (OR: 0.71; 0.57-0.87; favouring MDA), and PASDAS vs DAPSA (OR: 1.35; 1.10-1.66; favouring PASDAS). Supported by multivariate meta-analysis: MDA (OR: 5.06; 4.20-6.09), ACR20 (OR: 4.01; 3.41-4.73), PASDAS (OR:3.70; 3.00-4.56), DAPSA (OR: 3.02; 2.44-3.75), and CPDAI (OR: 1.86; 0.95-3.64). Sensitivity analyses confirmed a pattern of consistent numerical advantages for MDA and PASDAS. Exploratory analyses showed ACR70 had more discriminant capacity than ACR20 and DAPSA but not ACR50, MDA, and PASDAS. CONCLUSIONS: ACR20, MDA, and PASDAS demonstrated greater discriminant capacity than DAPSA. Exploratory analyses suggested greater discriminant capacity for ACR70 compared with ACR20 and DAPSA but not with ACR50, MDA or PASDAS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Section for Biostatistics and Evidence-Based Research, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark. Electronic address: Tommy.Kok.Annfeldt@regionh.dk.
- Section for Biostatistics and Evidence-Based Research, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; Research Unit OPEN at Department of Clinical Research, University of Southern Denm…
- Section for Biostatistics and Evidence-Based Research, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; Research Unit of Rheumatology, Department of Clinical Research, University of Sout…
- Section for Biostatistics and Evidence-Based Research, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.
- Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
- Department of Medicine/Rheumatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, P…
Förderung
- The Oak Foundation USA
Zitieren
APA
Annfeldt, T. K., Händel, M. N., Haugegaard, T., Henriksen, M., Coates, L. C., Ogdie, A., Tillett, W., Goel, N., Gladman, D. D., Orbai, A. M., de Wit, M., Strand, V., Mease, P. J., FitzGerald, O., Helliwell, P. S., Tugwell, P., Leung, Y. Y., & Christensen, R. (2026). Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials: a GRAPPA-OMERACT systematic review and network meta-analysis. Annals of the Rheumatic Diseases, 85(8), 1530-1542. https://doi.org/10.1016/j.ard.2026.05.013
Vancouver
Annfeldt TK, Händel MN, Haugegaard T, Henriksen M, Coates LC, Ogdie A, et al. Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials: a GRAPPA-OMERACT systematic review and network meta-analysis. Annals of the Rheumatic Diseases. 2026;85(8):1530-1542. doi:10.1016/j.ard.2026.05.013
BibTeX
@article{Annfeldt2026,
author = {Annfeldt, Tommy K and Händel, Mina N and Haugegaard, Tobias and Henriksen, Marius and Coates, Laura C and Ogdie, Alexis and Tillett, William and Goel, Niti and Gladman, Dafna D and Orbai, Ana-Maria and de Wit, Maarten and Strand, Vibeke and Mease, Philip J and FitzGerald, Oliver and Helliwell, Philip S and Tugwell, Peter and Leung, Ying-Ying and Christensen, Robin},
title = {Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials: a GRAPPA-OMERACT systematic review and network meta-analysis},
journal = {Annals of the Rheumatic Diseases},
year = {2026},
volume = {85},
number = {8},
pages = {1530--1542},
doi = {10.1016/j.ard.2026.05.013}
}
EUVIMED